MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563793 | Name: RG7834
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RG7834, also known as RO7020322, is a novel oral HBV viral gene expression inhibitor that blocks viral antigen and virion production. RG7834 is highly selective for HBV, and has a unique antiviral profile that is clearly differentiated from nucleos(t)ide analogues.

Chemical Structure

RG7834
RG7834
CAS#2072057-17-9 (S-isomer)

Theoretical Analysis

MedKoo Cat#: 563793

Name: RG7834

CAS#: 2072057-17-9 (S-isomer)

Chemical Formula: C22H27NO6

Exact Mass: 401.1838

Molecular Weight: 401.46

Elemental Analysis: C, 65.82; H, 6.78; N, 3.49; O, 23.91

Price and Availability

Size Price Availability Quantity
5mg USD 150.00 Ready to ship
10mg USD 250.00 Ready to ship
25mg USD 550.00 Ready to ship
50mg USD 950.00 Ready to Ship
100mg USD 1,650.00 Ready to Ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
199482-36-3 (S-isomer hydrate) 2072057-17-9 (S-isomer) 2072057-18-0 (R-isomer) 1802407-46-0 (racemic)
Synonym
RG7834; RG 7834; RG-7834; RO7020322; RO 7020322; RO-7020322
IUPAC/Chemical Name
(6S)-6-Isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
InChi Key
KBXLMOYQNDMHQT-KRWDZBQOSA-N
InChi Code
InChI=1S/C22H27NO6/c1-13(2)17-8-14-9-21(29-7-5-6-27-3)20(28-4)10-15(14)18-11-19(24)16(22(25)26)12-23(17)18/h9-13,17H,5-8H2,1-4H3,(H,25,26)/t17-/m0/s1
SMILES Code
O=C(C1=CN2[C@H](C(C)C)CC3=CC(OCCCOC)=C(OC)C=C3C2=CC1=O)O
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
RG7834 is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.
In vitro activity:
In cells expressing HBV mRNA, both PAPD5/7 were found to be physically associated with the viral RNA, and the polyadenylating activities of PAPD5/7 were susceptible to RG7834 repression in a biochemical assay. Reference: Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00640-20. https://pubmed.ncbi.nlm.nih.gov/33046485/
In vivo activity:
When human blood stem cells engineered to carry dyskeratosis congenita (DC)-causing PARN mutations were xenotransplanted into immunodeficient mice, oral treatment with RG7834 rescued TERC 3' end maturation and telomere length. These findings could help develop systemic telomere therapeutics to counteract stem cell exhaustion in DC, pulmonary fibrosis, and possibly other aging-related diseases. Reference: Cell Stem Cell. 2020 Jun 4;26(6):896-909.e8. https://pubmed.ncbi.nlm.nih.gov/32320679/
Solvent mg/mL mM
Solubility
DMSO 100.0 249.10
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 401.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sun L, Zhang F, Guo F, Liu F, Kulsuptrakul J, Puschnik A, Gao M, Rijnbrand R, Sofia M, Block T, Zhou T. The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00640-20. doi: 10.1128/AAC.00640-20. PMID: 33046485; PMCID: PMC7927841. 2. Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack JC, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25. PMID: 29079285. 3. Bopst M, Dinklo T, Funk J, Greiter-Wilke A, Lenz B, Kustermann S, Jiang T, Xie J. Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitor. Regul Toxicol Pharmacol. 2023 Jun;141:105407. doi: 10.1016/j.yrtph.2023.105407. Epub 2023 May 2. PMID: 37141985. 4. Nagpal N, Wang J, Zeng J, Lo E, Moon DH, Luk K, Braun RO, Burroughs LM, Keel SB, Reilly C, Lindsley RC, Wolfe SA, Tai AK, Cahan P, Bauer DE, Fong YW, Agarwal S. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell. 2020 Jun 4;26(6):896-909.e8. doi: 10.1016/j.stem.2020.03.016. Epub 2020 Apr 21. PMID: 32320679; PMCID: PMC7275922.
In vitro protocol:
1. Sun L, Zhang F, Guo F, Liu F, Kulsuptrakul J, Puschnik A, Gao M, Rijnbrand R, Sofia M, Block T, Zhou T. The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00640-20. doi: 10.1128/AAC.00640-20. PMID: 33046485; PMCID: PMC7927841. 2. Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack JC, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25. PMID: 29079285.
In vivo protocol:
1. Bopst M, Dinklo T, Funk J, Greiter-Wilke A, Lenz B, Kustermann S, Jiang T, Xie J. Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitor. Regul Toxicol Pharmacol. 2023 Jun;141:105407. doi: 10.1016/j.yrtph.2023.105407. Epub 2023 May 2. PMID: 37141985. 2. Nagpal N, Wang J, Zeng J, Lo E, Moon DH, Luk K, Braun RO, Burroughs LM, Keel SB, Reilly C, Lindsley RC, Wolfe SA, Tai AK, Cahan P, Bauer DE, Fong YW, Agarwal S. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell. 2020 Jun 4;26(6):896-909.e8. doi: 10.1016/j.stem.2020.03.016. Epub 2020 Apr 21. PMID: 32320679; PMCID: PMC7275922.
1: Kato D, Choy RW, Canales E, Dick RA, Lake AD, Shapiro ND, Chin E, Li J, Zhang JR, Wu Q, Saito RD, Metobo S, Aktoudianakis E, Schroeder SD, Yang ZY, Glatt DM, Balsitis S, Gamelin L, Yu M, Cheng G, Delaney WE 4th, Link JO. Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873. ACS Med Chem Lett. 2024 Mar 22;15(4):546-554. doi: 10.1021/acsmedchemlett.4c00037. PMID: 38628802; PMCID: PMC11017420. 2: Song H, Yang S, Wu S, Qin X, Wang Y, Ma X, Gong J, Wei M, Wang A, Wang M, Lan K, Guo J, Liu M, Chen X, Li Y, Lv K. Identification of dihydroquinolizinone derivatives with nitrogen heterocycle moieties as new anti-HBV agents. Eur J Med Chem. 2024 Mar 15;268:116280. doi: 10.1016/j.ejmech.2024.116280. Epub 2024 Feb 28. PMID: 38458109. 3: Li Y, Hwang N, Snedeker A, Lemon SM, Noe D, Sun L, Clement JA, Zhou T, Tang L, Block T, Du Y. "PROTAC" modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro. Bioorg Med Chem Lett. 2024 Apr 1;102:129680. doi: 10.1016/j.bmcl.2024.129680. Epub 2024 Feb 29. PMID: 38428537; PMCID: PMC11155259. 4: Bopst M, Dinklo T, Funk J, Greiter-Wilke A, Lenz B, Kustermann S, Jiang T, Xie J. Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitor. Regul Toxicol Pharmacol. 2023 Jun;141:105407. doi: 10.1016/j.yrtph.2023.105407. Epub 2023 May 2. PMID: 37141985. 5: Chu CM, Yu HH, Kao TL, Chen YH, Lu HH, Wu ET, Yang YL, Lin CH, Lin SY, Tsai MM, Chien YH, Hwu WL, Chen WP, Lee NC, Tseng CK. A missense variant in the nuclear localization signal of DKC1 causes Hoyeraal-Hreidarsson syndrome. NPJ Genom Med. 2022 Oct 30;7(1):64. doi: 10.1038/s41525-022-00335-8. PMID: 36309505; PMCID: PMC9617742. 6: Hu Y, Sun F, Yuan Q, Du J, Hu L, Gu Z, Zhou Q, Du X, He S, Sun Y, Wang Q, Fan L, Wang L, Qin S, Chen S, Li J, Wu W, Mao J, Zhou Y, Zhou Q, Zhang G, Ding CZ. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Bioorg Med Chem Lett. 2022 Nov 1;75:128977. doi: 10.1016/j.bmcl.2022.128977. Epub 2022 Sep 8. PMID: 36089112. 7: Li Y, Misumi I, Shiota T, Sun L, Lenarcic EM, Kim H, Shirasaki T, Hertel- Wulff A, Tibbs T, Mitchell JE, McKnight KL, Cameron CE, Moorman NJ, McGivern DR, Cullen JM, Whitmire JK, Lemon SM. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2204511119. doi: 10.1073/pnas.2204511119. Epub 2022 Jul 7. PMID: 35867748; PMCID: PMC9282228. 8: Qin X, Yang L, Ma X, Jiang B, Wu S, Wang A, Xu S, Wu W, Song H, Du N, Lv K, Li Y, Liu M. Identification of dihydroquinolizinone derivatives with cyclic ether moieties as new anti-HBV agents. Eur J Med Chem. 2022 Aug 5;238:114518. doi: 10.1016/j.ejmech.2022.114518. Epub 2022 Jun 8. PMID: 35700597. 9: Hwang N, Sun L, Noe D, Lam PYS, Zhou T, Block TM, Du Y. Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. ACS Med Chem Lett. 2021 Jun 22;12(7):1130-1136. doi: 10.1021/acsmedchemlett.1c00228. PMID: 34267883; PMCID: PMC8274061. 10: Sun L, Zhang F, Guo F, Liu F, Kulsuptrakul J, Puschnik A, Gao M, Rijnbrand R, Sofia M, Block T, Zhou T. The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00640-20. doi: 10.1128/AAC.00640-20. PMID: 33046485; PMCID: PMC7927841. 11: Shukla S, Jeong HC, Sturgeon CM, Parker R, Batista LFZ. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita. Blood Adv. 2020 Jun 23;4(12):2717-2722. doi: 10.1182/bloodadvances.2020001848. PMID: 32559291; PMCID: PMC7322949. 12: Menne S, Wildum S, Steiner G, Suresh M, Korolowicz K, Balarezo M, Yon C, Murreddu M, Hong X, Kallakury BV, Tucker R, Yang S, Young JAT, Javanbakht H. Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus. Hepatol Commun. 2020 Apr 22;4(6):916-931. doi: 10.1002/hep4.1502. PMID: 32490326; PMCID: PMC7262289. 13: Nagpal N, Wang J, Zeng J, Lo E, Moon DH, Luk K, Braun RO, Burroughs LM, Keel SB, Reilly C, Lindsley RC, Wolfe SA, Tai AK, Cahan P, Bauer DE, Fong YW, Agarwal S. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell. 2020 Jun 4;26(6):896-909.e8. doi: 10.1016/j.stem.2020.03.016. Epub 2020 Apr 21. PMID: 32320679; PMCID: PMC7275922. 14: Hyrina A, Jones C, Chen D, Clarkson S, Cochran N, Feucht P, Hoffman G, Lindeman A, Russ C, Sigoillot F, Tsang T, Uehara K, Xie L, Ganem D, Holdorf M. A Genome-wide CRISPR Screen Identifies ZCCHC14 as a Host Factor Required for Hepatitis B Surface Antigen Production. Cell Rep. 2019 Dec 3;29(10):2970-2978.e6. doi: 10.1016/j.celrep.2019.10.113. PMID: 31801065. 15: Mueller H, Lopez A, Tropberger P, Wildum S, Schmaler J, Pedersen L, Han X, Wang Y, Ottosen S, Yang S, Young JAT, Javanbakht H. PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization. Hepatology. 2019 Apr;69(4):1398-1411. doi: 10.1002/hep.30329. Epub 2019 Mar 1. PMID: 30365161. 16: Han X, Zhou C, Jiang M, Wang Y, Wang J, Cheng Z, Wang M, Liu Y, Liang C, Wang J, Wang Z, Weikert R, Lv W, Xie J, Yu X, Zhou X, Luangsay S, Shen HC, Mayweg AV, Javanbakht H, Yang S. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Dec 13;61(23):10619-10634. doi: 10.1021/acs.jmedchem.8b01245. Epub 2018 Oct 17. PMID: 30286292. 17: Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack JC, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25. PMID: 29079285.

1. Nagpal N, Agarwal S. Extension of replicative lifespan by synthetic engineered telomerase RNA in patient induced pluripotent stem cells. Nat Biomed Eng. 2025 Jun 27. doi: 10.1038/s41551-025-01429-1. Epub ahead of print. PMID: 40579489.